GivastomigVIS-101Ragistomig (ABL503)Uliledlimab Givastomig Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” presentation A Phase Ib dose escalation study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma Download “Mini Oral Presentation at the ESMO GI 2025 Annual Congress” PDF Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody Download “Poster presentation at the 2024 SITC meeting” PDF Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Download “Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors Download “First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors” PDF CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation Download “CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation” PDF Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer Download “Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer” PDF TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies Download “TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies” PDF Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation Download “Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation” PDF VIS-101 Phase 1 Study of VIS-101 (Anti-VEGF-A/Ang-2 Bispecific Antibody) for Diabetic Macular Edema (DME) Download “Phase 1 Study of VIS-101 (Anti-VEGF-A/Ang-2 Bispecific Antibody) for … Safety, Tolerability and Efficacy of Intravitreal VIS-101 for Neovascular Age-Related Macular Degeneration (CONQUER) Download “Safety, Tolerability and Efficacy of Intravitreal VIS-101 for Neovasc… Ragistomig (ABL503) Phase 1 Clinical Trial of Ragistomig (ABL503/TJ-L14B: PD-L1 x 4-1BB Bispecific Antibody) Q6W Dosing Balances Favorable Safety and Sustained Efficacy Through Extended Immunologic Memory and Reinvigoration of CD8+ T Cells Download “Poster presentation at the 2025 ESMO IO meeting” PDF Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors Download "Poster presentation at the 2024 ASCO meeting" PDF Uliledlimab Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, in Non-Small Cell Lung Cancer Patients Download “Poster presentation at the WCLC 2024” PDF
Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” presentation
Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF Download “Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” presentation
A Phase Ib dose escalation study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma Download “Mini Oral Presentation at the ESMO GI 2025 Annual Congress” PDF
Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody Download “Poster presentation at the 2024 SITC meeting” PDF
Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Download “Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF
Download “Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)” PDF
First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors Download “First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors” PDF
Download “First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors” PDF
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation Download “CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation” PDF
Download “CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation” PDF
Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer Download “Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer” PDF
Download “Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer” PDF
TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies Download “TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies” PDF
Download “TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies” PDF
Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation Download “Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation” PDF
Download “Claudin 18.2 - 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation” PDF
Phase 1 Study of VIS-101 (Anti-VEGF-A/Ang-2 Bispecific Antibody) for Diabetic Macular Edema (DME) Download “Phase 1 Study of VIS-101 (Anti-VEGF-A/Ang-2 Bispecific Antibody) for …
Safety, Tolerability and Efficacy of Intravitreal VIS-101 for Neovascular Age-Related Macular Degeneration (CONQUER) Download “Safety, Tolerability and Efficacy of Intravitreal VIS-101 for Neovasc…
Phase 1 Clinical Trial of Ragistomig (ABL503/TJ-L14B: PD-L1 x 4-1BB Bispecific Antibody) Q6W Dosing Balances Favorable Safety and Sustained Efficacy Through Extended Immunologic Memory and Reinvigoration of CD8+ T Cells Download “Poster presentation at the 2025 ESMO IO meeting” PDF
Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors Download "Poster presentation at the 2024 ASCO meeting" PDF
Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, in Non-Small Cell Lung Cancer Patients Download “Poster presentation at the WCLC 2024” PDF
